Find information on thousands of medical conditions and prescription drugs.

Elitek

Rasburicase is a recombinant urate oxidase enzyme. It is used for the prevention and treatment of tumor lysis syndrome in patients receiving chemotherapy for hematologic cancers such as leukemias and lymphomas.

It catalyses the conversion of uric acid to allantoin. Allantoin is much more soluble than uric acid, so renal excretion is more effective.

Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Research and Markets: Market Leaders in Oncology 2004 - Roche and Genentech Continue to Blaze a Trail
From Business Wire, 1/24/05

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c12125) has announced the addition of Market Leaders in Oncology 2004 - Roche and Genentech Continue to Blaze a Trail to their offering.

Roche continues to lead the oncology sector, recording oncology sales of $5,719m in 2003. This sector dominance is predicted to continue between 2004 and 2010, due to Roche's ability to combine strong sales and marketing with an innovative R&D policy.

Scope

--The oncology franchises of Bristol-Myers Squibb (BMS), AstraZeneca, Pfizer, Sanofi-Aventis and the Roche-Genentech partnership are examined

--Forecasts of future sales growth along with identification of potential blockbuster drugs and future market leaders

--Examination of the current oncology market and future directions in the search for innovative and profitable oncology products

Highlights

--The global oncology market continues to be dominated by Roche, whose growth was driven primarily by healthy sales of MabThera/Rituxan (rituximab), which saw sales rise 20.9% in 2003 to $2,063m. It is predicted that Roche will continue to dominate the oncology sector over the forecast period of 2003-10.

--BMS is experiencing problems. Its main oncology product, Erbitux (cetuximab), while expected to show healthy growth from 2003-10, is the only major product in its marketed portfolio. Revenue growth from 2003-10 is expected to come mainly from its subsidiary Oncology Therapeutic Network (OTN).

--AstraZenecas oncology portfolio has taken a serious hit due to negative outcome of the ISEL trial (Iressa Survival Evaluation in Lung Cancer). The results, released on December 17, 2004, indicate that Iressa (gefitinib) does not significantly prolong survival in patients with non-small cell lung cancer (NSCLC).

Reasons to Purchase

--Understand the current oncology market and who the market leaders are

--Identify where future growth for the sector is predicted to come from, and who the market leaders are predicted to be by 2010

--Identify and understand trends within the oncology sector to facilitate strategic development

CHAPTER 1 EXECUTIVE SUMMARY 6

Introduction 6

Scope and coverage of the Brief 6

Oncology portfolios key findings 9

CHAPTER 2 LEADING ONCOLOGY PLAYERS 10

CHAPTER 3 BMS: CAN THE COMPANY SUSTAIN AN ONCOLOGY PRESENCE? 15

Oncology franchise: marketed products 15

Erbitux: the survival chord between an outdated franchise and the next era? 17

Oncology franchise: pipeline analysis 21

Ixabepilone (BMS-247550) 22

The future 23

CHAPTER 4 ASTRAZENECA: CAN IT SUCCESSFULLY REPOSITION? 25

Oncology franchise: marketed products 25

Iressa: AstraZeneca's great hope falls from grace 28

Oncology franchise: pipeline analysis 30

The future 31

CHAPTER 5 PFIZER: THE 'ACQUIRE-A-FRANCHISE' MODEL 34

Oncology franchise: marketed products 34

Camptosar and Ellence: cytotoxic experience in two very different markets 35

R&D compounds 39

SU11248 40

J-107088 (endotecarin) 41

The future 41

CHAPTER 6 SANOFI-AVENTIS: PLAYING CATCH-UP TO SURVIVE? 44

Oncology franchise 44

Marketed products 44

Taxotere (docetaxel) 45

Current market position 46

Future sales growth 46

Campto (irinotecan) 47

Eloxatin (oxaliplatin) 47

Market position 48

Future sales 48

Eligard/Leuprogel (leuprolide acetate subcutaneous depot injection) 49

Fasturtec/Elitek (rasburicase) 50

R&D compounds 51

Tirazone (tirapazamine) 52

Future sales 52

Gastrimmune/G17DT 52

Future sales 53

The future 53

CHAPTER 7 THE ROCHE-GENENTECH PARTNERSHIP: THE MOST SUCCESSFUL PARTNERSHIP IN HISTORY? 55

On the origin of the species: the Roche-Genentech partnership 56

Strength and weaknesses of the partnership for Genentech 56

Strength and weaknesses of the partneship for Roche 56

Oncology franchise 57

Marketed products: Roche and Genentech 57

MabThera/Rituxan (rituximab) 59

Market position 59

Future sales 60

Herceptin (trastuzumab) 61

Avastin/anti-VEGF 63

Roche-Genentech's R&D compounds 65

Tarceva/R1415/OSI-774 66

Future partnership of Roche-Genentech: overall view 67

CHAPTER 8 APPENDIX 69

For more information visit http://www.researchandmarkets.com/reports/c12125

COPYRIGHT 2005 Business Wire
COPYRIGHT 2005 Gale Group

Return to Elitek
Home Contact Resources Exchange Links ebay